Ibex Investors LLC Has Stake in BiondVax Pharmaceuticals Ltd. (BVXV)
Ibex Investors LLC
recently revealed that they own 5.5% of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, September 22nd. The investor owns 14,342,370 shares of the stock worth approximately $101,113,709. The reporting parties listed on the disclosure included Ibex Investors LLC, Justin B Borus and Ibex Israel Fund Lllp. The filing is available through Edgar at this hyperlink.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) traded down 1.33% during mid-day trading on Friday, reaching $7.05. The company’s stock had a trading volume of 12,263 shares. BiondVax Pharmaceuticals Ltd. has a one year low of $3.04 and a one year high of $8.50. The firm’s 50 day moving average is $7.22 and its 200-day moving average is $7.22. The stock’s market cap is $31.65 million.
BiondVax Pharmaceuticals Profile
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Want to see what other hedge funds are holding BVXV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV).
Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.